Targeting fibroblast activation protein inhibits endothelial-mesenchymal transition by affecting cancer-associated fibroblasts derived exosomes

Author: Kai-Jia ZHANG ¹ ; Xiu -Rong ZHANG ¹ ; Shu-Shu WANG ¹ ; Wang-Kai CAO ² ; Hou-Xin ZHAO ³ ; Jia-Yu CUI ³ ; Bao-Gang ZHANG ³ ; Li-Hong SHI ⁴
Author Information

1. Shandong Province Key Laboratory of Applied Pharmacology, Weifang Medical University
2. Weifang Chest Hospital
3. College of Clinical Medicine, Weifang Medical University
4. College of Rehabilitation Medicine, Weifang Medical University
Publication Type:Journal Article
Keywords: angiogenesis; cancer-associated fibroblasts; endothelial cells; endothelial-mesenchymal transition; exosomes; fibroblast activation protein; Stat3
From: Chinese Pharmacological Bulletin 2023;39(9):1682-1689
CountryChina
Language:Chinese
Abstract: Aim To investigate whether targeted inhibition of fibroblast activation protein (FAP) can inhibit the endothelial-to-mesenchymal transition (EndMT) of vascular endothelial cells by affecting exosomes (Exo) of cancer-associated fibroblasts (CAFs) and explore the underlying mechanisms. Methods Primary CAFs and peri-tumor fibroblasts (PTFs) were obtained from lung cancer and peri-cancer tissues, and CAFs-exo and PTFs-exo were collected from culture medium, respectively. Exosomes from CAFs treated with specific FAP inhibitor (3.3 nmol • L-